IN8bio, a Phase 1 oncology biotech developing allogeneic gamma-delta T cell therapies, postponed its IPO on Friday. It had filed to raise $75 million by offering 4.7 million shares at a price range of $15 to $17.
The New York, NY-based company was founded in 2016 and had planned to list on the Nasdaq under the symbol INAB. Barclays, Cantor Fitzgerald and Mizuho Securities were set to be the joint bookrunners on the deal.
